Pular para conteúdo

Talassemia Beta Intermediária e Menor\_

Indução farmacológica da síntese da hemoglobina fetal

Terapia com Hidroxiureia (Hidroxicarbamida)\_

Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (abre nova janela)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Fonte‎: Hemoglobin 2014;38(1):44-8.

Indexado‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (abre nova janela)

Hydroxyurea in thalassemia intermedia--a promising therapy. (abre nova janela)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Fonte‎: Ann Hematol 2005;84(7):441-6.

Indexado‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (abre nova janela)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (abre nova janela)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Fonte‎: J Clin Pathol 2010;63(2):147-50.

Indexado‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (abre nova janela)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (abre nova janela)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Fonte‎: Eur J Haematol 2010;84(1):52-8.

Indexado‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (abre nova janela)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (abre nova janela)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Fonte‎: Blood Cells Mol Dis 2000;26(5):453-66.

Indexado‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (abre nova janela)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (abre nova janela)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Fonte‎: Ann N Y Acad Sci 2005;1054:250-6.

Indexado‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (abre nova janela)

Eritropoetina Recombinante (Isolada ou Combinada com Outros Agentes)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (abre nova janela)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Fonte‎: Acta Haematol 2004;111(4):189-95.

Indexado‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (abre nova janela)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (abre nova janela)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Fonte‎: Blood Purif 2004;22(5):453-60.

Indexado‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (abre nova janela)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (abre nova janela)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Fonte‎: Br J Haematol 2011;154(2):281-4.

Indexado‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (abre nova janela)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (abre nova janela)

Thein SL.

Fonte‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indexado‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (abre nova janela)